Author Archives: admin


Stem cells may be the key to saving white rhinos from extinction – Sciworthy

It is too late for conservation efforts to save the northern white rhinoceros, but with recent scientific advancements there may still be hope to bring back this beloved species. In a recently published paper, scientist Marisa Korody and her colleagues at San Diego Zoo Global (USA) and at the Department of Molecular Medicine at Scripps Research (USA) describe their exciting progress on using stem cells to revive the northern white rhino.

The northern white rhino is functionally extinct, meaning there are not enough of these rhinos left to save the species. In fact there are only two northern white rhinos left: a mother and a daughter. But for decades, scientists have preserved cell samples from 15 northern white rhinos containing enough genetic material to potentially bring this species back from the brink. These preserved samples hold fibroblast cells the type of skin cells that secrete collagen from white rhinos. With these scientists newly developed methods, fibroblast cells can be converted into something much more valuable: induced pluripotent stem cells. These stem cells can differentiate into any cell type in the body including heart cells, muscle cells, and reproductive cells.

In theory, by converting fibroblast cells into reproductive cells, scientists could create genetically unique rhino embryos. Alongside other assisted reproduction technologies, scientists could implant a new embryo into a closely-related southern white rhino, where the baby northern white rhino could develop as an otherwise normal pregnancy. By completing this process multiple times, scientists may be able to establish a stable population of northern white rhinos.

In 2011, this research team generated induced pluripotent stem cells from the samples of another endangered species, but unfortunately since this process was found to harm the recipient genomes, this method was largely unsuccessful. Despite this setback, in 2015 the authors met with colleagues worldwide to consider ways to save the northern white rhino, and they concluded that methods involving induced pluripotent stem cells may still be the most promising solution. Over the following years, the scientists worked to improve their methods, and these improvements are documented in their recent paper. These experiments represent the first step in a long-term plan to bring the northern white rhino back through assisted reproduction techniques.

Right from the start, the scientists faced a whole host of challenges. Through trial and error they modified the growth medium for the cells, optimizing it for rhinoceros cells. With their improved growth medium, scientists successfully generated induced pluripotent stem cell lines from 11 rhinoceros individuals. This has never been done before and represents a huge stride forward in the path to recovering this species.

Before trying to make their first rhino, the scientists needed to stress these induced pluripotent stem cells and sequence their genomes to determine if the cell quality is good enough to potentially produce new, viable rhinos. They maintained colonies of these cells in long-term cultures and exposed these colonies to different conditions to give insight into how resilient these cells could be. These tests demonstrated that long-term culture did not affect the potential for these cells to differentiate into cardiac lineage cells, confirming that these cells are stable long-term. The researchers also confirmed that these pluripotent cells could potentially produce gametes, the egg and sperm cells that are used for sexual reproduction. These advancements indicate that with these newly developed protocols, induced pluripotent stem cells are a promising tool that could someday help recover the northern white rhino.

Although this study includes some exciting results, there is still much work to do. For example, scientists must now sequence the genomes of the northern and southern white rhino so other researchers can analyze the stem cells ability to stay the same over time. Despite the work that still needs to be done, these promising advancements could someday help the northern white rhino population recover. This method may also work for saving other endangered or extinct species, as long as the genetic material needed is available. Long-term, these scientists plan to continue a series of experiments that could ultimately bring this beloved rhino, and potentially other endangered species, back from the brink of extinction.

Original study: Rewinding Extinction in the Northern White Rhinoceros: Genetically Diverse Induced Pluripotent Stem Cell Bank for Genetic Rescue

Study published on: February 15, 2021

Study author(s): Marisa L. Korody, Sarah M. Ford, Thomas D. Nguyen, Cullen G. Pivaroff, Iigo Valiente-Alandi, Suzanne E. Peterson, Oliver A. Ryder, and Jeanne F. Loring

The study was done at: San Diego Zoo Global (USA), Scripps Research (USA)

The study was funded by: San Diego Zoo Global and San Diego Zoo Wildlife Conservancy donors, including Anne and Christopher Lewis, and the Robert Kleberg and John and Beverly Stauffer Foundations; and Uma Lakshmipathy from Thermo Fisher Scientific for providing supplies

Raw data availability: Contact author for data (all other data are accessible from the article or supplementary materials)

Featured image credit: Hein waschefort, CC BY-SA 3.0, via Wikimedia Commons

Excerpt from:
Stem cells may be the key to saving white rhinos from extinction - Sciworthy

Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here’s The Tech Behind It – Tech Times

RJ Pierce, Tech Times 05 October 2021, 09:10 am

Healthcare research has gone a long way from the dark days of old, when today's simplest illnesses can be a death sentence. And now, there's reason to look forward to a brighter future because of this news.

(Photo : Getty Images )

According to BigThink, a team from Iowa State University claimed that they've found a way to integrate human immune systems in pigs, as a way to study illnesses much closer.

In other words, they basically "humanized" the pigs to try and find out how to better treat human diseases in the future.

The implications of their research are quite profound, too. As per the researchers, this breakthrough could theoretically advance healthcare research in areas such as virus and vaccines, cancer, and even stem cell treatments.

Before this, scientists often used mice in their biotech and biomedical experiments. However, the problem is that mice-based results don't translate well to humans.

Aside from mice, primates have also been used in related fields of healthcare research due to their direct biological connections with humans. Nevertheless, a lot of ethical issues popped up, thus leading to the retirement of primates, including chimpanzees, from this type of research eight years ago.

This won't be the first time that healthcare research has produced what's basically human-animal hybrids to study illnesses.

Three years ago, a team of scientists from Rockefeller University in New York managed to create a human-chicken embryo, in an attempt to take a closer look at the intricacies of stem cell therapies.

Read also: Scientists Want To Create Part-Human Part-Animal Chimeras To Find Cure For Diseases

It started when the same scientists from Iowa State University discovered a genetic mutation in pigs that caused an illness called SCID (Severe Combined Immunodeficiency).

Some people may know this from the film "The Boy In The Plastic Bubble" from 1976, which tells the story of a child whose immune system never fully developed. As such, he was forced to literally live inside a sterile bubble because even the slightest cold would kill him.

Upon this discovery, the researchers then developed a pig that's far more immunocompromised compared to a person with SCID, then successfully "humanized" it by injecting human immune stem cells into the livers of piglets.

The researchers were able to do this by using ultrasound imaging as a guide.

Ultrasound imaging, also known as sonography, makes use of high-frequency waves to look inside the body.

(Photo : Getty Images )

The resulting pigs had excellent healthcare research potential, because they were found to have human immune cells in their blood, thymus gland, spleen, and liver.

However, the SCID-afflicted pigs are in constant danger of infections. As such, they have to be housed in so-called bubble biocontainment facilities. These facilities work by maintaining high positive pressure, which keeps dangerous pathogens out. All staff members have to wear sterile protective gear at all times.

They've basically turned into their own versions of the boy in the bubble.

Before this research, pigs have often been used to know more about the human body because of how strikingly similar their anatomy is to humans.

In fact, a few scientists even believe that with how biologically similar pigs are to humans, they might be classified into an animal family occupied by primates, reportedScience.org.au.

But of course, there have been ethical issues involving the use of these human-animal hybrids for healthcare research. Eventually, though, the National Institutes of Health (NIH) relaxed their regulations a bit back in 2016, which made it easier for scientists to transfer human stem cells into animal embryos.

Related: Scientists Grow Sheep Embryos With Human Cells To Revolutionize Organ Transplant

This article is owned by Tech Times

Written by RJ Pierce

2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Visit link:
Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times

Global Allogenic Stem Cell Therapy Market 2021 Size, Share, Growth and Regional Analysis by Segmentation and Country Forecast to 2028 – Digital…

The Report Published by Data Bridge Market Research on Allogenic stem cell therapy Market 2021, This report provides details of Market analysis, size, share and forecast, trends, growth drivers, and challenges, as well as vendor analysis. The company profiles of all the dominating market manufacturers and brands that are making moves such as product launches, joint ventures, mergers, and acquisitions are described in the report. It also becomes easy to analyse the actions of key players and respective effect on the sales, import, export, revenue, and CAGR values. The market data of the Allogenic stem cell therapy report is useful for businesses in characterizing their individual strategies. Allogenic stem cell therapy market report estimates the size of the market with respect to the information on key merchant revenues, development of the industry by upstream and downstream, industry progress, key companies, along with market segments and application.

Allogenic stem cell therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 10.10% in the above-mentioned forecast period.

Get Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-allogenic-stem-cell-therapy-market

The Major Players Covered In The Allogenic Stem Cell Therapy Market Report Are

Objective Of The Report

To analyze strategies/developments such as collaborations, agreements, partnerships, mergers and acquisitions, and product launches and developments in the Allogenic stem cell therapy market

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Allogenic stem cell therapy market.

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Allogenic stem cell therapy Market

The key findings and recommendations highlight crucial progressive industry trends in the Allogenic stem cell therapy Market, thereby allowing players to develop effective long term strategies

To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Allogenic Stem Cell TherapyMarket Scope and Market Size

Allogenic stem cell therapy market is segmented on the basis of product type, cell source, application and end users. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-allogenic-stem-cell-therapy-market

Objectives Of Allogenic Stem Cell Therapy Report:

Allogenic Stem Cell TherapyMarket Drivers:

The rapid development in infrastructure for stem cell banking has been directly impacting the growth of allogenic stem cell therapy market.

The high growth of advanced genome-based cell analysis techniques has been driving the market and is acting as a potential driver for the allogenic stem cell therapy market over the forecast period of 2020 to 2027.

The rising awareness correlated to the therapeutic potency of stem cells in effective disease management is also contributing towards the growth of the target market.

The growing public-private investments for the expansion of stem cell therapies, growth in infrastructure related to stem cell banking and processing along with increase in prevalence of chronic diseases such as cardiovascular diseases andcanceras well as increase in funding for stem cell research are also increasing the allogenic stem cell therapy market size.

Moreover, the rising awareness totherapeutic potencyof stem cells in disease organization is actively driving the growth of the target market. In addition, the appearance of IPSCS as an efficient substitute to ESCS and supportive regulations across emerging countrieswill flourish various growth opportunities for the allogenic stem cell therapy market in the above mentioned forecast period.

However, the uncertain regulatory guidelines for product development and commercialization as well as socio-ethical issues coupled with the use of ESCS in disease treatment will hamper the growth of the allogenic stem cell therapy market in the forecast period of 2020 to 2027.

Allogenic Stem Cell TherapyMarket Restraints:

Thetechnical limitations associated with production scale-up will pose as a challenge towards the growth of the market in the above mentioned forecast period.

Focus Of The Report:

The study provides an in-depth analysis of the global Allogenic stem cell therapy market and current & future trends to elucidate imminent investment pockets.

Changing market dynamics of the industry

Strategies of key players and product offerings

In-depth market segmentation

Recent industry trends and developments

Analyze and forecast Allogenic stem cell therapy market on the basis of type, function and application.

If Looking for Customization or any Doubt to Reach to us @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-allogenic-stem-cell-therapy-market

Key points for analysis in the report

Excerpt from:
Global Allogenic Stem Cell Therapy Market 2021 Size, Share, Growth and Regional Analysis by Segmentation and Country Forecast to 2028 - Digital...

Select residents with high-risk health issues will start getting a booster shot starting tomorrow – Newstalk 610 CKTB (iHeartRadio)

Select residents with high-risk health issues will start getting a booster shot starting tomorrow.

Niagara Health will be administering the shot to those with eligibility letters from their doctor.

High-risk populations: - Transplant recipients (including solid organ transplant and hematopoietic stem cell transplants) - Patients with hematological cancers (examples include lymphoma, myeloma, leukemia) on active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders - Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab) - Residents of high-risk congregate settings including long-term care homes, higher-risk licensed retirement homes and First Nations Elder Care Lodges

Eligibility letters are required for third doses and must include: - Dated and on letterhead - Contact information for physician, specialist or medical practice of individual completing the form - Patient's name (typed/generic letters will not be accepted) - List of specific criteria required for patient eligibility - Patient's eligible condition for third dose

Niagara Health will administer third COVID-19 vaccine doses starting Tuesday, Aug. 31 at our St. Catharines Site as walk-in only between 8 a.m. and 3 p.m. (closed between 12 and 1 p.m.) on a first-come, first-served basis.

Transplant recipients, patients with hematological cancers on active treatments and recipients of an anti-CD20 agent can receive their third dose at a minimum of eight weeks (56 days) following their second dose and will be contacted directly by their health care provider, such as their primary care provider, specialist or hospital specialty program.

Third doses will be offered to residents of long-term care homes and provincially-designated high-risk retirement homes at a minimum of five months following their second dose and will be co-ordinated through Public Health. Eligible high-risk populations with eligibility letters can also receive their third dose at any Niagara Region Public Health vaccination clinics.

For more information, please visit https://www.niagarahealth.on.ca/site/vaccination-clinic

Read more here:
Select residents with high-risk health issues will start getting a booster shot starting tomorrow - Newstalk 610 CKTB (iHeartRadio)

Princeton To Offer Third Dose Of COVID-19 Vaccine In September – Reverb MSN Music

Shutterstock

PRINCETON, NJ Beginning Sept. 20, the Princeton Health Department will offer booster doses to those who have had the Pfizer or Moderna COVID-19 vaccine for eight months, the department announced.

Princeton Health Department is expected to begin hosting regular booster clinics starting in September. More information on the details of these clinics will be released shortly, the department said in the newsletter.

A third vaccine dose for immunocompromised individuals is now available in the Garden State, a shot "intended to ensure that [immunocompromised people] have enough protection against COVID because they may not build up the same level of immunity as other people," said New Jersey Department of Health Commissioner Judy Persichilli during a Monday afternoon news conference.

Earlier in August, President Joe Biden announced that booster shots will be available starting Sept. 20. The FDA and the CDC have already authorized the third dose of either Pfizer or Modera COVID-19 vaccines for those who are moderate to severely immunocompromised.

Read more: COVID-19 Booster Shot Authorized For Immunocompromised

The plan is for a booster shot to eventually become available to all adults eight months after their second shot. The booster shot is free and does not require proof of ID or health insurance.

Those in active cancer treatment, those with uncontrolled HIV, organ or stem cell transplant recipients, those taking medications that weaken their immune systems such as chemotherapy or anti-rejection medication after a transplant, and disease-modifying antirheumatic drugs are currently eligible for a third dose. A full list of conditions can be found on the CDC website.

The state is currently determining point-of-distribution locations for the third dose in each county. Third dose mega-sites may also be in the cards, Persichilli added, noting that the state is prepared for a "range of scenarios."

Meanwhile, Mercer County is offering walk-in COVID-19 vaccine clinics for the unvaccinated. Here are the upcoming clinics:

Princeton Health Department Clinic

Princeton University Clinics (located in Jadwin Gym)

Mercer County Pop-Up Clinics

(With reporting from Nicole Rosenthal, Patch Staff)

Thank you for reading. Have a correction or news tip? Email sarah.salvadore@patch.com

Get breaking news alerts on your phone with our app. Download here. Sign up to get Patch emails so you don't miss out on local and statewide news.

Visit link:
Princeton To Offer Third Dose Of COVID-19 Vaccine In September - Reverb MSN Music

Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and – GlobeNewswire

WINSTON SALEM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.

The pandemic has shone a bright light on the need for clinical trial participation as never before in history, said Lilly Skok Bunch, Executive Director of Greater Gift. Greater Gift has been celebrating and acknowledging clinical trial participants for more than 10 years; this is the first time that a program will recognize trial participants in a way that also yields benefits for students with vision challenges.

Greater Gifts programs celebrate clinical trial participants by making donations on behalf of those individuals to reinforce the impact of their contribution on the advancement of clinical research. Celebrations of clinical trial participants have provided an additional benefit of 130,000 vaccines and meals to children in need through prior programs.

AGTC is thrilled to partner with Greater Gift to honor clinical trial participants and their families for their contribution to the clinical research community, said Halley Losekamp, Director of Patient Enrollment at AGTC. "Through this partnership, our goal is to enhance awareness within the community about the value of clinical trial participation in advancing the science and understanding of gene therapies in IRDs while underscoring AGTCs commitment to support the underserved communities that have limited access to vision care services.

Greater Gift partnered with 2020 On-site because of the organizations commitment to the underserved through their relationship with the Boston Public School System. This donation will allow 2020 On-site to continue the longstanding eye exam program and to double the impact of the gift, as they conduct their annual exam program and delivery of eyeglasses to public school students in need in Boston.

We are honored to be part of this partnership with AGTC and Greater Gift. Both companies align with our mission to make eye care more accessible and to increase trust in and awareness of clinical trials. Now, because of this relationship, we will be able to support even more Boston area school children to help them succeed in the coming school year and beyond, said Jessica Mays, Senior Director of Life Sciences for 2020 On-site, which uses their fleet of Mobile Vision Clinics to provide eye care both routinely and as part of ongoing clinical trials.

About Greater Gift (www.greatergift.org):Greater Gift is a non-profit organization, founded in 2010, with a mission to increase awareness of clinical research, especially among underrepresented communities, to improve global health. Greater Gift builds bridges with underrepresented communities to engage them in research, ensure equal representation in clinical research and to increase access to research as an option for medical care. Since its founding, Greater Gift has honored 130,000 clinical trial volunteers by making donations of vaccines and meals to children in need in their honor.

About AGTC: AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3). Its preclinical programs build on the Companys industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding.

About: 2020 On-site: 2020 On-site has been revolutionizing how vision care benefits are being delivered to companies and patients for 7 years. Its state-of-the-art mobile vision clinics serve over 450 companies in the greater Boston area. The company has also expanded its services to support BioPharma companies, CROs, and clinical sites to develop programs to assess their patients close to home, or even right at their front door. To learn more about how 2020 On-site is supporting clinical research, visit their website.

Contact: David Harrison david@harrisoncommunications.net 410-804-1728

View post:
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and - GlobeNewswire

Huntingtons disease: northern Scotland has one of world’s highest rates and rising sharply here’s why – The Conversation UK

Huntingtons disease (HD) is a devastating inherited neurodegenerative condition that causes a slow but relentless decline in mental health, thinking processes, speech, swallowing and balance, resulting in uncontrollable jerky movements.

Those who have the condition will eventually lose the ability to walk, talk, eat, drink, make decisions or care for themselves. A fatal condition, it typically takes between 15 and 25 years from a person developing symptoms until they die. These symptoms generally begin between the ages of 30 and 60 but can appear before or after this range.

The disease is caused by the faulty Huntingtin gene that expresses a toxic protein, (also called Huntingtin) which builds up and causes early brain-cell death. The child of someone with Huntingtons has a one in two chance of inheriting it, so people at risk grow up experiencing the impact on family members as they become aware of their own likelihood of getting the disease.

Although worldwide research is taking place, there is currently no cure for Huntingtons disease. However, the effects of many of its symptoms can be reduced with a combination of medication, dietary advice and non-medical therapies, including physiotherapy and speech therapy as well as appropriate social care and support.

Nearly 40 years ago, 9.94 per 100,000 people in the north of Scotland had symptoms of Huntingtons, compared to 5.4 per 100,000 elsewhere in the UK. Now our latest research has revealed that 14.6 people per 100,000 in this northernmost region have Huntingtons. The current figure for rest of the UK is 12.4 per 100,000, illustrating that rates are rising generally, but remain particularly high in Scotland.

Our research team decided to re-run a 1984 study that had examined the prevalence of Huntingtons in the Grampian region. We used medical records from labs and HD clinics across the Highlands and Grampian regions to count the number of people across the north of Scotland tested and diagnosed with the condition in the intervening years. Remarkably, we found that cases have increased by 46% since 1984.

In addition, over the last four years, 23% more people with no symptoms but a personal or family history of HD have had a genetic test to see if they will develop the condition possibly in the hope of taking part in trials that might slow the disease.

Our findings mean that northern Scotland has among the highest rates of Huntingtons disease in the world. Its prevalence is almost three times greater than reported elsewhere in Europe (4.7 per 100,000); North America (4.1-5.2 per 100,000); Japan (0.1 per 100,000); Australia (5.70 per 100,000 people) and more than five times the estimated worldwide rate of 2.71 per 100,000 people.

Since the identification of the Huntingtons gene in 1993 made testing for the condition possible, awareness has increased and a diagnosis can now be made in people unaware of their family history of the condition. Along with better care and hope of treatment trials, this has led to more people coming forward for testing.

We believe the high rates of HD diagnosis in Grampian and Highland are due to a combination of underlying genetic susceptibility in ancestral populations dating back to the rule of the Picts; increased awareness that diagnosis will lead to better care and support services; and the region having one of the oldest specialist Huntingtons research clinics in the world. Interestingly, there is also a higher incidence of of multiple sclerosis (MS) in the north of Scotland, though no equivalent genetic explanation for some of the cases.

We did note that the rates of Huntingtons also vary between the different health board regions in the north of Scotland, with more cases in Highland and fewer in Orkney and Shetland compared with Grampian. This local variation in rates could have major drug cost and service delivery implications for the NHS, especially if expensive, complexly administered therapies prove successful.

Although the condition is particularly common in northern Scotland, our data clearly shows that there is far more Huntingtons diagnosed now than the previous prevalence studies suggest, and more people with the HD gene are testing before the appearance of symptoms to access better care and research trials.

The increased diagnosis rate for Huntingtons is likely to be even greater in regions around the world where there has been no long-term focus on the diagnosis and management of the disease.

Health care providers worldwide should now assess local need for specialist services in the expectation that Huntingtons is more common than previously thought. They also need to plan for therapies that can help with the condition, making them part of routine clinical care by improving local services, providing Huntingtons clinics, and studying the prevalence of the disease in their country.

Read this article:
Huntingtons disease: northern Scotland has one of world's highest rates and rising sharply here's why - The Conversation UK

X-linked Adrenoleukodystrophy Market to Eyewitness Massive Growth by 2028 | Sanofi, Pfizer, J&J, Abbott, Merck, GSK UNLV The Rebel Yell – UNLV The…

Overview of the GlobalX-linked Adrenoleukodystrophy Market:

The Global X-linked Adrenoleukodystrophy Market is expected to grow at a CAGR of 7.10% in the forecast period of 2021 to 2028.

The top-notch X-Linked Adrenoleukodystrophy market research report has been structured by skilful and experienced team players who work hard to accomplish an absolute growth and success in the business. The marketing report acts upon market study and analysis to provide market data by considering new product development from beginning to launch. The key research methodology employed throughout this report by DBMR research team is data triangulation which entails data mining, analysis of the impact of data variables on the market, and primary validation. Adopting X-Linked Adrenoleukodystrophy market report is always beneficial for any company, whether it is small scale or large scale, for marketing its products or services.

Get a Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-x-linked-adrenoleukodystrophy-market .

As per the market report analysis, X-linked Adrenoleukodystrophy (X-ALD) is a rare genetic disorder. This condition is caused due to the abnormality in HEALTHCARED1 gene which is present on the X chromosome. It further results in the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. This accumulation in tissues leads to the damage of myelin which causes neurological problems in patients.

Some of the most significant key factors driving the growth of the Global X-linked Adrenoleukodystrophy Market are increase in the prevalence of X-linked adrenoleukodystrophy, inevitable inheritance of the disease, advancement of therapies for treatment, and increase in the awareness towards genetic diseases coupled with genetic counselling.

Regional analysis, North America dominates the X-Linked Adrenoleukodystrophy Market due to the existence of major key players, high prevalence rate, increasing social awareness, well-developed healthcare sector, and increase in the government support for research & development in this region. Global X-Linked Adrenoleukodystrophy Market in the APAC is expected to grow during the forecast period, because of growing focus of pharmaceutical companies on advancement of therapies for treatment of rare diseases, growing government support, and rising healthcare expenditure.

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-x-linked-adrenoleukodystrophy-market .

Major Key Players:

1 agtc

2 bluebird bio

3 MINORYX THERAPEUTICS SL

4 SwanBio Therapeutics, Inc

5 Viking Therapeutics

6 Novartis AG

7 Sanofi

8 Pfizer Inc

9 Sumitomo Corporation

10 Johnson & Johnson Private Limited

11 AstraZeneca

12 Cipla Inc

13 Abbott

14 Bayer AG

15 Merck KGaA

16 GlaxoSmithKline plc and More.

Global X-linked Adrenoleukodystrophy Market Segmentation:

Market Segment by Type:

1 Adrenomyeloneuropathy (AMN) 2 Adult Cerebral ALD 3 Childhood Cerebral ALD 4 Addisons-Only ALD

Market Segment By Symptoms:

1 Paraparesis 2 Adrenocortical Insufficiency 3 Psychiatric Disorders 4 Dementia Urinary and Genital Tract Disorders 5 Others

Market Segment By Treatment:

1 Stem Cell Transplant 2 Adrenal Insufficiency Treatment 3 Gene Therapy 4 Physical Therapy 5 Corticosteroids 6 Lorenzos Oil 7 Others

Market Segment By Diagnosis:

1 Blood Testing 2 MRI 3 Vision Screening 4 Skin Biopsy 5 Fibroblast Cell Culture

Market Segment By End-Users:

1 Clinics 2 Hospitals 3 Diagnostic Centres 4 Others

Get a TOC of Global X-linked Adrenoleukodystrophy Market Report 2021@ https://www.databridgemarketresearch.com/toc/?dbmr=global-x-linked-adrenoleukodystrophy-market .

A quality X-Linked Adrenoleukodystrophy business report has been planned with full commitment and transparency in research and analysis. The market analysis report enlists a number of market drivers and restraints which are derived from SWOT analysis and also provides all the CAGR projections for the historic year 2019, base year 2021, and forecast period of 2021-2028. The report puts a light on prospective and key opportunities in new geographical market. This universal X-Linked Adrenoleukodystrophy market report broadly comprises of absolute and distinct analysis of the market drivers and restraints, major market players involved in this industry, exhaustive analysis of the market segmentation, and competitive analysis of the key players.

Get Our More Trending Research Report Here:

1 Global Adrenoleukodystrophy Treatment Market Industry Trends and Forecast to 2027

2 Global X-Linked Hypophosphatemia (XLH) Treatment Market Industry Trends and Forecast to 2027

3 Global Hypophosphatemia Treatment Market Industry Trends and Forecast to 2027

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Read the original here:
X-linked Adrenoleukodystrophy Market to Eyewitness Massive Growth by 2028 | Sanofi, Pfizer, J&J, Abbott, Merck, GSK UNLV The Rebel Yell - UNLV The...

Alpha Thalassemia Market 2021 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 UNLV The Rebel Yell – UNLV The Rebel…

Latest research on Alpha Thalassemia Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2015-2021 together with a forecast from 2021 to 2027 supported by both volume and revenue (USD million). The entire study covers the key drivers and restraints for the Alpha Thalassemia market. this report included a special section on the Impact of COVID19. Also, Alpha Thalassemia Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends. The report also gives 360-degree overview of the competitive landscape of the Alpha Thalassemia industries.

The Alpha Thalassemia Market is expected to register a CAGR of around 8.7%, during the forecast period 2021 to 2027.

Click Here to Get Latest Sample PDF Copy of updated research 2021:

https://www.marketinsightsreports.com/reports/07123064363/global-alpha-thalassemia-market-size-status-and-forecast-2021-2027/inquiry?Mode=VIIIXX

Key Market Players: Bluebird Bio, Novartis, Kiadis Pharma, Acceleron Pharma

Market Segmentation by Types:

Iron Chelating Drugs

Gene Therapy

Market Segmentation by Applications:

Hospitals

Private Clinics

Other

Regions covered By Alpha Thalassemia Market Report 2021 to 2027 are

North America (The United States, Canada, and Mexico), Asia-Pacific (China, India, Japan, South Korea, Australia, Indonesia, Malaysia, and Others), Europe (Germany, France, UK, Italy, Russia, and Rest of Europe), Central & South America (Brazil, and Rest of South America), and Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, and Other).

Alpha Thalassemia Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 20212027.

Browse Full report description and TOC:

https://www.marketinsightsreports.com/reports/07123064363/global-alpha-thalassemia-market-size-status-and-forecast-2021-2027?Mode=VIIIXX

Influence of the Alpha Thalassemia Market Report:

-Comprehensive assessment of all opportunities and risks in the Alpha Thalassemia Market.

-Alpha Thalassemia Market recent innovations and major events.

-A detailed study of business strategies for the growth of the Alpha Thalassemia Market market-leading players.

-Conclusive study about the growth plot of Alpha Thalassemia Market for forthcoming years.

-In-depth understanding of Alpha Thalassemia market-particular drivers, constraints, and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Alpha Thalassemia Market.

The research includes historic data from 2015 to 2021 and forecasts until 2027 which makes the report an invaluable resource for industry executives, marketing, sales, and product managers, consultants, analysts, and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, the Alpha Thalassemia Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. The Alpha Thalassemia industry report additionally presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

For Early Buyers | Get Up to 20% Discount on This Premium Report:

https://www.marketinsightsreports.com/report/purchase/07123064363?mode=su?Mode=VIIIXX

We Offer Customization On Report Based On Specific Client Requirement:

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact UsIrfan Tamboli (Sales Manager) Market Insights Reports Phone: + 1704 266 3234 | +91-750-707-8687 sales@marketinsightsreports.com|irfan@marketinsightsreports.com

See the original post:
Alpha Thalassemia Market 2021 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 UNLV The Rebel Yell - UNLV The Rebel...

[PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell – UNLV The Rebel Yell

Stem cells are divided into two major classes; pluripotent and multipotent. Pluripotent stem cells are replicating cells, which are derived from the embryo or fetal tissues. The pluripotent stem cells facilitate the development of cells and tissues in three primary germ layers such as mesoderm, ectoderm, and endoderm.

Increasing expansion of facilities by market players for stem cell therapies is expected to propel growth of the stem cell therapy market over the forecast period. For instance, in January 2018, the University of Florida, U.S. launched the Center for Regenerative Medicine that is focused on development of stem cell therapies for the treatment of damaged tissue and organ. The Centre for Regenerative Medicines is divided into two segments such as focus groups and shared services. Focus groups such as research and development activities for stem cell therapies; and the shared services segment offers technical resources related to stem cell therapies.

FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/2848

*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report. Research Methodologyadopted for it.

Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market. For instance, in May 2018, Procella Therapeutics and Smartwise, a medtech company entered into a collaboration with AstraZeneca Pharmaceuticals. Under this collaboration, AstraZeneca utilized Procella Therapeutics stem cell technology for the development of stem cell therapies in cardiovascular diseases. Moreover, in April, 2019, CelluGen Biotech and FamiCord Group collaborated to develop new stem cell-based drugs and advanced medical therapies (ATMP)

Major Company Profiles Covered in This Report:Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2848

Increasing research and development activities by the market players are one of the major factors that are expected to drive growth of the stem cell therapy market over the forecast period. For instance, in July 2018, the Emory Orthopaedics & Spine Center, in collaboration withSanford Health, Duke University, Andrews Institute, and Georgia Institute of Technology, received US$ 13 million grant from the Marcus Foundationfor a multicenter clinical trial studying stem cell options for treating osteoarthritis.The Phase 3 trial was initiated in March 2019, and is expected to complete by December 2021. Moreover, in December 2017, Mayo Clinic initiated the clinical phase I study on safety and feasibility of mesenchymal stem cell therapy in patients with intracerebral hemorrhage. This therapy is used for treating acute spontaneous hemorrhagic stroke. The study is expected to complete by December 2020.

Moreover, increasing product launches by key players is expected to boost demand for stem cell therapy over the forecast period. For instance, in August 2017, LifeCell, a healthcare service provider, launched an advanced umbilical cord-stem cell collection kit which offers enhanced protection to neonatal stem cells from environmental damage and temperature fluctuations.

Inquire more about this report @https://www.coherentmarketinsights.com/insight/talk-to-analyst/2848

Frequently Asked Questions

What are the key factors driving Stem Cell Therapy Market expansion?

What will be the value of Stem Cell Therapy Market during 2020- 2027?

Which region will make notable contributions towards global Stem Cell Therapy Market revenue?

What are the key players leveraging Stem Cell Therapy Market growth?

Also, Research Report Examines:

Competitive companies and manufacturers in global market

By Product Type, Applications & Growth Factors

Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

See original here:
[PDF] Stem Cell Therapy Market Size Strong Revenue and Generated Opportunities UNLV The Rebel Yell - UNLV The Rebel Yell